Working… Menu

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (ADVOCATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02994927
Recruitment Status : Active, not recruiting
First Posted : December 16, 2016
Last Update Posted : July 8, 2019
Information provided by (Responsible Party):

Brief Summary:
The aim of the trial is to assess the safety and efficacy of the orally-administered, selective complement C5a receptor inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Condition or disease Intervention/treatment Phase
ANCA-Associated Vasculitis Drug: CCX168 Drug: Prednisone Drug: Cyclophosphamide Biological: Rituximab Drug: Azathioprine Phase 3

Detailed Description:

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated concomitantly with Rituximab or Cyclophosphamide/Azathioprine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine
Study Start Date : December 2016
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vasculitis

Arm Intervention/treatment
Experimental: CCX168 (avacopan)
CCX168 in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
Drug: CCX168
Orally administered
Other Name: Avacopan

Drug: Cyclophosphamide
Orally or intravenously administered

Biological: Rituximab
Intravenously administered

Drug: Azathioprine
Orally administered

Active Comparator: Prednisone
Prednisone in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
Drug: Prednisone
Orally administered

Drug: Cyclophosphamide
Orally or intravenously administered

Biological: Rituximab
Intravenously administered

Drug: Azathioprine
Orally administered

Primary Outcome Measures :
  1. Remission [ Time Frame: 26 weeks ]
    The proportion of patients achieving disease remission assessed by Birmingham Vasculitis Activity Score (BVAS) at Week 26

  2. Sustained remission [ Time Frame: 52 weeks ]
    The proportion of patients achieving sustained disease remission assessed by BVAS at Week 52

Secondary Outcome Measures :
  1. Adverse events coded by MedDRA [ Time Frame: 60 weeks ]
    Patient incidence of treatment-emergent serious adverse events, adverse events, and withdrawals due to adverse events

  2. Glucocorticoid-induced toxicity [ Time Frame: 26 weeks ]
    Glucocorticoid-induced toxicity as measured by the Glucocorticoid Toxicity Index

  3. Response rapidity [ Time Frame: 4 weeks ]
    Remission assessed by BVAS at week 4

  4. Health-related quality of life [ Time Frame: 52 weeks ]
    Change in health-related quality-of-life based on the Short Form-36 version 2 component and domain scores and the EuroQOL-5D-5L visual analogue scale (in mm) and index

  5. Estimated glomerular filtration rate (eGFR) [ Time Frame: 52 weeks ]
    Change from baseline in eGFR in mL/min/1.73^2

  6. Urinary albumin:creatinine ratio (UACR) [ Time Frame: 52 weeks ]
    Change from baseline in UACR in mg/g creatinine

  7. Urinary monocyte chemoattractant protein-1 (MCP-1):creatinine ratio [ Time Frame: 52 weeks ]
    Change from baseline in urinary MCP-1:creatinine ratio in pg/mg creatinine

  8. Vasculitis Damage Index [ Time Frame: 52 weeks ]
    Change from baseline in the Vasculitis Damage Index (VDI)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
  • Male and female subjects, aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with cyclophosphamide or rituximab is needed; where approved by Regulatory Agencies, adolescents (12-17 year old) may be enrolled
  • Use of adequate contraception
  • Positive test for anti-PR3 or anti-MPO
  • At least 1 major item, or at least 3 non-major items, or at least the 2 renal items of proteinuria and hematuria on BVAS
  • Estimated glomerular filtration rate ≥15 mL/minute/1.73 m^2 at screening

Exclusion Criteria:

  • Pregnant or breast-feeding
  • Alveolar hemorrhage requiring pulmonary ventilation support at screening
  • Any other known multi-system autoimmune disease
  • Required dialysis or plasma exchange within 12 weeks prior to screening
  • Have a kidney transplant
  • Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1
  • Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 weeks prior to screening
  • Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening
  • Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x10^9/L); received anti-TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening
  • For patients scheduled to receive cyclophosphamide treatment, urinary outflow obstruction, active infection (especially varicella zoster infection), or platelet count <50,000/μL before start of dosing
  • Participated previously in a CCX168 study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02994927

  Hide Study Locations
Layout table for location information
United States, Alabama
Huntsville, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, California
Los Angeles, California, United States
United States, Colorado
Aurora, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Daytona Beach, Florida, United States
Tampa, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Idaho
Meridian, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Kansas
Kansas City, Kansas, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Louisiana
Shreveport, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, New York
Great Neck, New York, United States
Mineola, New York, United States
New York, New York, United States
Rochester, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Greenville, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Cleveland, Ohio, United States
Columbus, Ohio, United States
United States, Pennsylvania
Duncansville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Providence, Rhode Island, United States
United States, South Carolina
Charleston, South Carolina, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Washington
Seattle, Washington, United States
Adelaide, Australia
Auchenflower, Australia
Brisbane, Australia
Clayton, Australia
Concord, Australia
Heidelberg, Australia
Liverpool, Australia
Nambour, Australia
Nedlands, Australia
Randwick, Australia
Saint Albans, Australia
Southport, Australia
St Leonards, Australia
Westmead, Australia
Woolloongabba, Australia
Feldkirch, Austria
Graz, Austria
Innsbruck, Austria
Antwerp, Belgium
Brussels, Belgium
Leuven, Belgium
Liège, Belgium
Calgary, Canada
Greenfield Park, Canada
Hamilton, Canada
Montréal, Canada
Québec, Canada
Sherbrooke, Canada
Toronto, Canada
Vancouver, Canada
Olomouc, Czechia
Praha, Czechia
Aalborg, Denmark
Aarhus, Denmark
Copenhagen, Denmark
Odense, Denmark
Roskilde, Denmark
Angers, France
Bordeaux, France
Boulogne-sur-Mer, France
Brest, France
Bron, France
Caen, France
Colmar, France
Grenoble, France
Marseille, France
Metz, France
Nantes, France
Nîmes, France
Paris, France
Toulouse, France
Valenciennes, France
Aachen, Germany
Bad Bramstedt, Germany
Berlin, Germany
Cologne, Germany
Dresden, Germany
Essen, Germany
Freiburg, Germany
Fulda, Germany
Hamburg, Germany
Hannöver, Germany
Heidelberg, Germany
Jena, Germany
Kirchheim unter Teck, Germany
Leipzig, Germany
Ludwigshafen, Germany
Lübeck, Germany
Mannheim, Germany
Munich, Germany
Tuebingen, Germany
Villingen-Schwenningen, Germany
Budapest, Hungary
Debrecen, Hungary
Cork, Ireland
Dublin, Ireland
Ancona, Italy
Firenze, Italy
Genova, Italy
Milano, Italy
Monza, Italy
Parma, Italy
Reggio Emilia, Italy
Torino, Italy
Udine, Italy
Aichi, Japan
Akita, Japan
Chiba, Japan
Hiroshima, Japan
Hokkaido, Japan
Ishikawa, Japan
Kagawa, Japan
Kanagawa, Japan
Kobe, Japan
Miyazaki, Japan
Nagoya, Japan
Okayama, Japan
Osaka, Japan
Saitama, Japan
Shimane, Japan
Shizuoka, Japan
Tokyo, Japan
Toyama, Japan
Yokohama, Japan
Groningen, Netherlands
Leiden, Netherlands
Rotterdam, Netherlands
New Zealand
Christchurch, New Zealand
Dunedin, New Zealand
Grafton, New Zealand
Hamilton, New Zealand
Takapuna, New Zealand
Nordbyhagen, Norway
Oslo, Norway
Tromsø, Norway
Badalona, Spain
Barcelona, Spain
Burela, Spain
Lleida, Spain
Madrid, Spain
San Sebastián, Spain
Linköping, Sweden
Lund, Sweden
Stockholm, Sweden
Uppsala, Sweden
Örebro, Sweden
Basel, Switzerland
Bern, Switzerland
Fribourg, Switzerland
Lausanne, Switzerland
St. Gallen, Switzerland
Zürich, Switzerland
United Kingdom
Aberdeen, United Kingdom
Basildon, United Kingdom
Birmingham, United Kingdom
Bristol, United Kingdom
Cambridge, United Kingdom
Canterbury, United Kingdom
Cardiff, United Kingdom
Carshalton, United Kingdom
Dorchester, United Kingdom
Dudley, United Kingdom
Exeter, United Kingdom
Glasgow, United Kingdom
Inverness, United Kingdom
Kirkcaldy, United Kingdom
Leeds, United Kingdom
Leicester, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Newcastle, United Kingdom
Nottingham, United Kingdom
Oxford, United Kingdom
Reading, United Kingdom
Salford, United Kingdom
Westcliff-on-Sea, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Director: Cass Kelleher, MD ChemoCentryx, Inc.

Additional Information:
Layout table for additonal information
Responsible Party: ChemoCentryx Identifier: NCT02994927     History of Changes
Other Study ID Numbers: CL010_168
ADVOCATE ( Other Identifier: ChemoCentryx )
First Posted: December 16, 2016    Key Record Dates
Last Update Posted: July 8, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by ChemoCentryx:
ANCA-associated vasculitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vascular Diseases
Cardiovascular Diseases
Systemic Vasculitis
Autoimmune Diseases
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antimetabolites, Antineoplastic